Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The CCTG PA.7 trial: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma met its target accrual of 180 patients on 26-JUL-2018 and is now officially closed to accrual.
The Canadian Cancer Trials Group (CCTG) Operations and Statistical Centre (OSC), based at the Queen’s University Cancer Research Institute in Kingston, Ontario is seeking a physician with hematology or oncology training with demonstrated interest and experience with developing and cancer therapy trials.
Senior investigators work at the OSC with members of the investigational new drug and disease-specific and trial endpoint committees, which have national investigator leadership and membership, to develop and implement the CCTG clinical trials research agenda.
The DTL has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network Trial (NCTN) where CCTG is using the DTL is the BLC.4 trial. An active DTL is now a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other upcoming studies that will be using the DTL initially include MAC.24 and REC.4.
The results of the Canadian Cancer Trials Group (CCTG) BL.12 phase II randomized trial were presented at ASCO 2018 by Dr. Srikala Sridhar, the BL.12 Study Chair. In this interview Dr. Sridhar discusses the BL.12 study and what is next for bladder cancer clinical trial research.
The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC). Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals.
The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4.
